US Executive Compensation Proxy SEC Filings — September 04, 2026

04-09-2026

iBio, Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders to be held on October 14, 2026. The meeting will include votes on six proposals: election of two Class III directors, ratification of Grassi & Co. as auditor, an advisory say-on-pay vote, an amendment to increase authorized common shares to 500,000,000, an amendment to the 2023 Omnibus Incentive Plan's evergreen provision, and an adjournment proposal. The Board recommends a 'FOR' vote on all proposals.

• · The 2026 Annual Meeting will be held on October 14, 2026 at 1:00 p.m. Pacific Time at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.
• · The record date for determining stockholders entitled to vote is September 1, 2026.
• · Proxy materials will be mailed on or about September 14, 2026.
• · Proposal 5 amends the evergreen provision of the 2023 Omnibus Incentive Plan: for 2027-2029, the annual increase is 5% of outstanding common stock plus 3% of shares issuable upon exercise of pre-funded warrants; for 2030-2033, the increase is 5% of outstanding common stock only.
• · Proposal 6 is an adjournment proposal to allow further solicitation if there are insufficient votes for Proposal 4 or Proposal 5.

04-09-2026

IB Acquisition Corp. filed a definitive proxy statement (DEF 14A) seeking stockholder approval to extend the deadline to complete a business combination beyond March 25, 2027. The filing warns that if the extension is not approved or a deal is not completed, the company may be forced to liquidate, returning approximately $10.05 per share to public stockholders. However, the company faces significant risks including potential Nasdaq delisting, insufficient cash after redemptions, and a possible 1% U.S. federal excise tax on share repurchases, which could materially impact shareholder value.

• · The deadline to complete a business combination is March 25, 2027.
• · If the extension is not approved, Nasdaq will delist the securities.
• · The company may be subject to a 1% U.S. federal excise tax on redemptions under the Inflation Reduction Act of 2022.
• · CFIUS review could block or delay a business combination with a U.S. target.
• · If liquidated, public shareholders receive $10.05 per share and rights expire worthless.

04-09-2026

Grown Rogue International Inc. filed its definitive proxy statement (DEF 14A) on September 4, 2026, for its annual and special meeting of shareholders scheduled for October 26, 2026. The meeting will cover the election of directors, appointment of auditors, approval of an amended long-term equity incentive plan, and a special resolution to consolidate shares on a basis of up to 30 pre-consolidation shares for 1 post-consolidation share. The filing does not contain any financial results or period-over-period comparisons, so no positive or negative performance metrics are available.

• · Meeting date: October 26, 2026 at 11:00 a.m. EDT at Miller Thomson LLP, Toronto.
• · Record date for voting: August 31, 2026.
• · Share consolidation proposal: up to 30 pre-consolidation shares for 1 post-consolidation share (special resolution).
• · Auditor appointment: Turner, Stone & Company, L.L.P.
• · Paper copy request deadline: October 19, 2026.
• · All dollar references are in Canadian dollars unless specified as US$.

04-09-2026

CACI International Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Shareholders to be held virtually on October 15, 2026. The meeting will include the election of 10 director nominees, a non-binding advisory vote on named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2027. The filing provides standard governance proposals with no disclosed financial results or performance metrics.

• · Record date for shareholders entitled to vote is August 21, 2026.
• · The annual meeting will be conducted virtually at www.virtualshareholdermeeting.com/CACI2026.
• · Shareholders may vote via Internet, phone, or mail, and can change their vote by attending the virtual meeting.
• · The proxy statement and annual report are available at investor.caci.com/events.

04-09-2026

Hartford Schroders Private Opportunities Fund is holding a Special Meeting of Shareholders on September 21, 2026, to vote on three key proposals: electing six new Board nominees, approving a new advisory agreement with Schroder Investment Management North America Inc. (SIMNA), and approving a new sub-advisory agreement with Schroders Capital Management (US) Inc. These proposals are part of a broader 'Fund Adoption Transaction' that will also change the Fund's name to 'Schroders Capital Private Opportunities Fund' and replace service providers. The proposals are cross-conditional, meaning all three must pass for the transaction to proceed; if any fails, the current structure remains. The Board recommends voting FOR all proposals.

• · The Fund Adoption Transaction includes a name change to 'Schroders Capital Private Opportunities Fund'.
• · The Fund's investment objective, investment strategy, portfolio managers, and advisory fee are not expected to change as a result of the proposals.
• · Nuveen, LLC has announced a proposed acquisition of Schroders plc, which will cause an automatic termination of current sub-advisory agreements, necessitating the new agreements.
• · If shareholders do not approve all three proposals, the current Board, investment adviser (HFMC), sub-adviser (SIMNA), and sub-sub-adviser (Schroders Capital) will continue in their roles.
• · The Board has approved interim sub-advisory agreements to ensure continuity of services pending shareholder approval.
• · Shareholders of record as of August 21, 2026, are entitled to vote, with one vote per share and no cumulative voting.
• · Schroders will pay all expenses related to the proxy solicitation and meeting.

04-09-2026

BioLife Solutions is being acquired by Repligen Corporation in a merger expected to close in Q4 2026. BioLife stockholders will receive a mix of cash and Repligen common stock, and are expected to own approximately 11.1% of the combined company. Stockholders have appraisal rights under Delaware law if they do not favor the merger.

• · Merger is structured as a two-step merger (First Merger and Second Merger) qualifying as a reorganization under Section 368(a) of the Code.
• · Stockholders who do not vote in favor and meet strict procedural requirements may seek appraisal under Delaware Section 262.
• · Conditions to closing include stockholder approval, HSR Act waiting period expiration, SEC registration effectiveness, and Nasdaq listing of Repligen shares.
• · BioLife stockholders will recognize gain (but not loss) on the exchange, limited to cash received (excluding cash in lieu of fractional shares).
• · BioLife's principal offices are in Bothell, Washington; Repligen is headquartered in Waltham, Massachusetts.

04-09-2026

Taylor Devices, Inc. filed its DEF 14A proxy statement for the fiscal year ended May 31, 2026, detailing director and executive compensation. Total compensation for CEO Timothy J. Sopko decreased to $519,026 in FY2026 from $631,696 in FY2025, while CFO Paul M. Heary's total compensation fell to $422,394 from $484,083. No bonuses were paid to NEOs for FY2026, and net income declined to $8,563,675 from $9,413,136 in the prior year, though total shareholder return improved to $277 per $100 investment from $199.

• · No bonuses were paid to NEOs for FY2026 under the Management Bonus Policy, which caps aggregate bonuses at 15% of net income.
• · Director compensation includes quarterly retainers ($11,000 for Chairman, $7,000 for other non-employee directors) plus meeting fees ($2,000 Audit, $1,000 Nominating, $1,000 Compensation).
• · On April 18, 2026, each director and CFO received options to purchase 7,000 shares at an exercise price of $56.43, the fair market value on April 17, 2026.
• · CEO Timothy J. Sopko's base salary increased to $329,600 in FY2026 from $320,000 in FY2025, while CFO Paul M. Heary's base salary increased to $245,140 from $238,000.
• · Employment agreements for Sopko and Heary provide for 12 months of base salary continuation and COBRA premium reimbursement upon termination without cause or non-renewal by the company, plus a 12-month non-competition clause.
• · Major shareholders include Wax Asset Management (9.23%), BlackRock (5.52%), and Vanguard (5.16%).

04-09-2026

Paychex filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders, highlighting strong fiscal 2026 financial performance with total service revenue of $6.3B (up 16% YoY), operating income of $2.5B (up 14% YoY), and diluted EPS of $4.89 (up 7% YoY). The company returned $2.2B to stockholders through dividends ($1.6B) and share repurchases ($611.0M), and increased its quarterly dividend by 10% to $1.19 per share. However, annual cash incentive payouts for executives were only 64% of target, reflecting a significant shortfall against goals, and no performance-based equity awards vested during the fiscal year due to an extended performance period.

• · Quarterly dividend increased by 10% to $1.19 per share in May 2026.
• · 5.6 million shares repurchased for $611.0 million in fiscal 2026.
• · CEO and NEO annual cash incentive payouts were 64% of target for fiscal 2026.
• · Performance-based equity awards comprise 60% of total long-term incentive value at target, subject to a three-year performance period ending May 31, 2027.
• · No performance periods for performance-based equity awards concluded during fiscal 2026.
• · Ten director nominees proposed; Ms. Wilson will not stand for reelection.
• · Board refreshment is a priority based on stockholder feedback.
• · Paychex recognized as one of World's Most Ethical Companies for the 18th time.
• · Paychex Flex and Paycor platforms named 'Leader' in NelsonHall HCM technology and GenAI evaluation.
• · Two 2026 Lighthouse Tech Awards received for Paychex Flex and Paycor platforms.

04-09-2026

Standex International Corporation filed its DEF 14A proxy statement for the 2026 Annual Meeting, scheduled for October 20, 2026. The filing includes the election of three director nominees, an advisory vote on executive compensation, and ratification of auditors. CEO David Dunbar's total compensation for FY 2026 was $6,407,973, with a base salary of $936,436 and stock awards of $4,135,819, while other named executive officers received significantly lower total compensation, ranging from $800,704 to $2,164,717.

• · Record date for voting is August 25, 2026.
• · Internet and telephone voting available until 1:00 a.m. ET on October 20, 2026.
• · All non-employee directors are independent.
• · Policy against hedging and pledging of company stock.
• · SEC-compliant clawback policy in place.
• · Mandatory Board retirement age.
• · Stock ownership requirements for directors and executive officers.
• · Oversight of ESG strategy and reporting.

04-09-2026

Jasper Therapeutics filed a definitive proxy statement (DEF 14A) for a special meeting of stockholders on September 30, 2026, seeking approval for a reverse stock split (range 1-for-15 to 1-for-35) to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a deficiency notice on June 3, 2026, and an increase in authorized common shares from 490,000,000 to 675,000,000 shares to facilitate the conversion of preferred stock issued in connection with the acquisition of Kira Pharmaceuticals on July 16, 2026. The closing price of common stock on September 3, 2026 was $0.6864 per share, well below the $1.00 threshold, and the company has not yet regained compliance. The board recommends voting FOR all proposals but reserves the right not to implement the reverse split or share increase if deemed not in the company's best interest.

• · Nasdaq deficiency notice received June 3, 2026; initial 180-day cure period ends November 30, 2026.
• · Company has not regained compliance as closing bid price has not been at least $1.00 for ten consecutive business days.
• · Board reserves right not to implement reverse split or share increase if deemed not in best interest.
• · Board does not currently intend to effect the authorized share increase if the reverse stock split is effected.
• · Merger with Kira Pharmaceuticals closed on July 16, 2026.
• · Record date for special meeting: August 10, 2026.
• · Proxy statement first mailed on or about September 9, 2026.

04-09-2026

Sanara MedTech Inc. is being acquired by MiMedx Group, Inc. in a cash-and-stock merger valued at approximately $35.00 per share. The Sanara Board unanimously recommends shareholders vote FOR the merger at a special meeting on September 30, 2026. However, the stock component of the consideration is subject to market fluctuation, and post-merger Sanara shareholders will own only about 2.9% of the combined company.

• · Special Meeting will be held on September 30, 2026 at 9:00 a.m. Central Time, virtually at www.virtualshareholdermeeting.com/SMTI2026SM.
• · Shareholders of record as of the record date (not specified) must use a 16-digit control number to attend the virtual meeting.
• · The Merger Agreement was signed on July 29, 2026.
• · Certain Sanara shareholders entered into a Voting Agreement to vote in favor of the Merger Proposal and against any alternative acquisition proposal.
• · The Merger Consideration is subject to adjustment as described in the proxy statement/prospectus.
• · The stock component of the Merger Consideration will fluctuate with the market price of MiMedx Common Stock.
• · The Sanara Board unanimously recommends voting FOR the Merger Proposal, the Advisory Compensation Proposal, and the Adjournment Proposal.